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Down modulation of Heymann's nephritis by mercuric chloride. The
time course of Heymann's nephritis (HN), assessed on proteinuria and
immunotnorphology, has been compared in Lewis (LEW) rats immu-
nized with BB alone (group A) or injected with HgC12 and subsequently
immunized in a similar manner (group B). Whereas all rats from group
A developed typical HN characterized by heavy proteinuria and
abundant glomerular immune deposits, rats from group B did not
develop or developed a markedly attenuated form of HN; proteinuria
was never detectable, immune deposits were absent or minimal. No
abnormalities were found in rats injected with HgC12 alone. In order to
explain our findings, we have studied the glomerular and tubular
expression of the 330 kD nephritogenic glycoprotein (gp330) as well as
the corresponding antibody response. In rats receiving HgCl2, gp330
was normally expressed on BB and glomerular epithelial cells as
indicated by in vitro and in vivo binding of anti-gp330 antibodies, but
titers of anti-BB and anti-gp330 antibodies were considerably lower
than in group A control rats. These findings therefore suggest that
HgCl2 acts by its immunodepressive effect recently related to an
increase in T suppressor cells. This effect is paradoxical since HgCl2
induces autoimmunity in Brown—Norway rats, and we suggest that it
may be akin to observations reported in clinical practice where drugs
may be immunostimulatory in some patients and immunodepressive in
others. The mercury model may therefore represent a unique tool to
evaluate the relationship between genetics and drug—induced immune
dysregulation.
Mercuric chloride is responsible for the induction of mem-
branous nephropathy (MN) in outbred Wistar rats [1] and in
several other strains, including BN rats [2, 3]. In the latter it
also induces anti-glomerular basement membrane (GBM) anti-
bodies prior to the appearance of subepithelial deposits [4, 5].
In contrast, studies from our laboratory show that rats with the
RTl1 haplotype such as Lewis (LEW) rats do not develop
autoimmune glomerulonephritis (GN) when injected with HgC12
[6]. It is well known that LEW rats are highly susceptible to the
development of active Heymann's nephritis [7], following im-
munization with brush border (BB) antigen. Experiments based
on passive administration of anti-BB antibodies in ex vivo [8] or
isolated perfused kidney [91 have shown that the antigen
responsible for this classical model of MN was also expressed
by glomerular epithelial cells. The inability of HgC12 to induce
autoimmune GN in LEW rats was somewhat surprising, since it
has been suggested that tubular damage induced by various
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toxins, such as mercury or gold salts, could induce MN in man
110] or animals [11].
The aim of the present study was therefore to assess whether
HgCl2 could alter the time course of Heymann's nephritis in
LEW rats. The recent identification of the antigen involved as a
330 kD glycoprotein [12, 13] made it possible to analyze the
cellular expression of the target antigen as well as the produc-
tion of nephritogenic antibodies. It will be shown that, surpris-
ingly, HgCI2 markedly lessens or even prevents Heymann's
nephritis in LEW rats.
Methods
Animals
Ten- to 14-week—old male LEW rats initially obtained from
the CSEAL (CNRS, Orleans-La Source, France) and main-
tained by brother—sister mating in our animal house, were used
in this study.
Experimental procedure
Three groups of rats were tested. Nine rats (group A) were
injected with 2 mg of BB antigen prepared as F x 1A fraction
[141 and further purified by sedimentation on a 41% sucrose
cushion [15]. The antigen, emulsified in CFA, was injected in
the rear footpads of the animals without any booster injections.
In order to serve as controls for the following groups, these rats
were also injected with water adjusted to pH 4, as described in
the mercury model [4]. Ten rats (group B) were subcutaneously
injected three times a week with HgC12 (0.1 mg/lOO g body wt)
as previously described [41 for eight weeks. Two weeks after
the first injection of HgC12 they were immunized with the BB
antigen as described for group A. Five rats (group C) were
injected with HgCl2 only as described for group B. All the rats
were killed at the sixth week following immunization or, for
group C rats, following the first injection of HgCl2.
Proteinuria
The 24-hour urinary protein excretion was measured once a
week using the Biuret method. Rats were maintained overnight
in metabolic cages with free access to water, but without food.
Immunomorphological studies
Kidney cryostat sections were obtained from all rats and
tested by direct immunofluorescence (IF) using a fluorescein-
ated sheep, anti-rat IgG conjugate as described elsewhere [4].
The intensity of IgG deposits was scored from 0 to 4. Four
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samples were also fixed in 1.5% glutaraldehyde and processed
for electron microscopy as previously described [I].
Circulating anti-BB and anti-gp330 antibodies
Five rats in each group were bled on day 0 and then once a
week. Serum samples were diluted 1/20 and assayed for the
presence of anti-BB antibodies by indirect immunotluorescence
on normal kidney cryostat sections. Tissue bound immunoglob-
ulins were revealed with the fluoresceinated anti-rat IgG anti-
serum. Results were graded from 0 to 3. Serum samples were
also tested for the presence of anti-gp 330 antibodies using an
ELISA. Glycoprotein 330 was prepared as previously reported
[161 by affinity chromatography on Sepharose 4 B (Pharmacia,
les Ulis, France) immobilized monoclonal antibody. Two hun-
dred d of a 1 jsglml solution of antigen were incubated at 37°C
for three hours in 96-well microtiter plates (Nunclon, Den-
mark). After washing with phosphate buffered saline (PBS)
containing 0.05% Tween 20, wells were incubated for two hours
at room temperature with 1/400 dilutions in PBS Tween of the
sera to be tested. After washing, solid—phase bound IgG were
revealed with biotin—labeled anti-rat IgG (International Corp.,
Amersham, U.K.) followed by peroxidase—labeled streptavidin
(International Corp.) as previously described [17]. All samples
were tested in duplicate.
Antibody response to sheep red blood—cells
Five normal LEW rats and five LEW rats which had received
either H20 adjusted to pH 4 or HgCI2 for 14 days were also
immunized with an unrelated antigen. They were intravenously
injected on days 15 and 23 with 500 p1 of a suspension of sheep
red blood—cells (SRBC) at 4. 109/ml in 9°/cc NaCl. The anti-
SRBC antibody response was measured by hemagglutination on
days 0, 7 and 14 following the first injection of SRBC.
Round—bottomed microtiter plates (Nunc, Copenhagen, Den-
mark) were filled with 25 p1 of the suspension of SRBC Sera to
be tested were decomplemented and serially diluted from 1/8 to
1/640, Plates were filled with 25 p1 of each dilution, incubated at
37°C for 60 minutes and then examined microscopically. Re-
suits were expressed as the logarithm (log.2) of the last positive
dilution SD.
Renal expression of gp330
In order to ascertain that gp330 was expressed similarly in
rats receiving HgCl2 and in control rats, indirect immunofiuo-
rescence was performed on frozen kidney sections from two
normal rats and from two HgCl2-injected rats. In each case,
mouse monoclonal antibodies specific for four distinct epitopes
on gp330 [131 and rabbit polyclonal antibodies [16] were used,
Kidney bound Igs were revealed by using the adequate
fluoresceinated anti-IgG antiserum.
In viva binding of anti-gp 330 antibodies
The ability of anti-gp330 antibodies to bind in vivo to the
glomerulus was studied in HgCI2-injected rats and in rats
injected with the control solution for two weeks. In each case,
two to three rats were killed 72 hours after an intravenous
injection of 5, 50, 100, 200 or 600 p1 of rabbit anti-gp330
antiserum. Kidney cryostat sections were then performed and
studied by indirect immunofluorescence as previously de-
scribed.
Statistical analysis
Statistical analysis was carried out by Student's f-test for
paired and non-paired groups according to the experimental
design. All results are expressed as the mean 1 SD.
Results
Proteinuria
As shown in Figure 1, urinary protein excretion increased in
group A rats from the third week, and these rats exhibited
significant proteinuria after three weeks, reaching approxi-
mately 100 mg/day afer one month. In sharp contrast, urinary
protein excretion did not increase (<20 mg per day) at any time
in rats from group B (immunized with BB antigen and HgCl2
injected) or in group C rats injected with HgCI2 only (data not
shoWn).
Immunomorphologicalfindings
As expected, all the rats immunized with BB antigen alone
(group A) exhibited typical granular IgG deposits along glomer-
ular capillary wall at the time of sacrifice (Fig. 2A). In addition,
eight of the nine rats also had granular IgG deposits along the
basement membrane of proximal convoluted tubules (PCT).
Results observed in rats who received HgCl2 and were then
immunized with BB antigen two weeks later (group B) were
strikingly different. Four rats had no detectable Ig deposits (Fig.
2B). In the other six, granular IgG deposits along the glomerular
capillary wall were very small and scanty (Fig. 2C). Rare
granular deposits along the BB of a few PCT were seen in only
three of these. The results scored semi-quantitatively in Table 1
clearly show that granular Ig deposits along the glomerular
capillary walls and tubular basement membranes were signifi-
cantly less in group B rats than in group A rats. No glomerular
or tubular granular IgG deposits were seen at any time in group
C rats.
Renal tissue from two rats of group A and from two rats of
group B was studied by electron microscopy. Typical stage 3
MN [181 was seen in the two rats from group A, while only few
scattered subepithelial electron—dense deposits, mainly local-
120
100
80
'
20
0
Time, days after Immunization with FX1 A
Fig. 1. Daily urinary protein excretion in group A rats immunized with
a pur jfied fraction ofF X JA antigen (hatched bars) and in group B rats
injected with HgC!2 and then immunized with the antigen (white bars).
Values presented are mean I su. Difference between both groups is
significant on days 22 (P < 0.02), 31 (P < 0.01) and 39 (P < 0.001).
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Fig. 2. Kidney cryostat sections obtained at the time ofsacrjfice from group A rats immunized with a purified fraction ofF X IA antigen (A) and
from group B rats injected with HgCI2 and then immunized with the antigen (B, C). Sections were stained with a fluoresceinated anti-rat IgG
antiserum. A. Typical granular IgG deposits, regularly distributed along all the glomerular capillary walls in a group A rat. Note also the presence
of few granular deposits along the basement membrane of some proximal convoluted tubules (x 460). B. Example of a group B rat with negative
immunofluorescence findings at the time of sacrifice. Photograph has been deliberately overexposed (x 460). C. Example of a group B rat with
scanty and dispersed granular IgG deposits along some glomerular capillary walls (X 690).
Group
Granular IgG depositsa Anti-BB antibodies"
Day 14 Day 22Glomerular Tubular
A 2.2 1.9
(9)
1.9
(5)
2
B o.3c
(10)
0.25c
(a)
12d
0 (5) 0 0 (5) 0 (5)
a Kidney cryostat sections were studied by direct immunofluores-
cence at the time of sacrifice. Values are mean 1 SD.
b The presence of anti-BB antibodies was assessed by indirect
immunofluorescence. Values presented are mean values at the
peak SD. Numbers in parentheses represent the number of rats
tested.
P < 0.001
d P < 0.01
P < 0.005 when compared to group A rats.
ized in the mesangial area (stage 1), were observed in the two
rats from group B.
Circulating anti-gp330 and anti-BB antibodies
Anti-gp330 were clearly detectable (Fig. 3) on day 22 in rats
immunized with BB antigen (group A) and remained at a high
level until the end of the experiment. Antibody level increased
slightly in group B rats (HgCI2-injected and then immunized
with BB antigen). However the difference was not significant
when values were compared to initial values. Values were
significantly lower when compared to those obtained in group A
rats on days 22 and 31. Anti-gp330 abs were not detected in rats
from group C injected with HgCl2 alone (not shown).
Indirect immunofluorescence showed that anti-BB antibodies
were present in both groups A and B with a peak on days 14 and
14 22 31 39
Time, days
Fig. 3. Serum anti-gp330 antibodies assessed by an ELISA in group A
rats immunized with a purified fraction of F x 1A antigen (hatched
bars) and in group B rats, injected with HgCI2 and then immunized with
the antigen (white bars). Results are expressed as the mean optical
density (O.D.) I SD. The increase in antibody titer is significant in
group A, but not in group B. Difference between both groups is
significant on days 22 (P < 0.01) and 31 (P < 0.02).
22, but the mean score was again lower in group B rats (Table
I). Anti-BB antibodies were not detected in group C rats.
Antibody response to sheep red blOod—cells
As shown in Table 2, the primary antibody response (day 7)
and the secondary antibody response (day 14) were significantly
lower in rats injected with HgCl2 when compared to those
observed in LEW rats immunized with SRBC only. However
the secondary antibody response was less affected.
Table 1. Immunofluorescence findings
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Table 2. Anti-sheep red blood cells antibody response in normal
and HgCI2-injected LEW rats
Hemagglutination
HgCI2 N rats
Log2 of the last positive dilution on day
0 7 14
—
+
5
5
0
0
6.4 0.5a
1.6±2"
7.4 0.5
6±1.2c
Mean SD
b p < 0,001
P < 0.05
In vitro and in vivo binding of anti-gp330 antibodies
In vitro binding of the four monoclonal antibodies and of the
polyclonal antiserum was identical in control rats and in HgCb-
injected rats. Typical binding was noted in the four rats tested
on the BB and on the glomerular epithelial cells. On the latter,
the fluorescence was fine, and dispersed along the glomerular
capillary wall [12, 171.
In vivo injection of 5 to 600 d of rabbit anti-gp330 antiserum
induced granular IgG deposits typical of passive Heymann's
nephritis in HgCl2-injected rats (Fig. 4). The extent and inten-
sity of deposits were strictly identical to those observed in
control rats, including those having the threshold dose of 5 d.
Discussion
Mercuric chloride can induce immune dysregulation and
glomerular disease in BN [4, 5, 19] and in PVG/c 12, 3, 20] rats,
while other strains with a different RT-1 haplotype, such as
LEW rats, are resistant [2, 6]. In this study we show that, in
LEW rats, HgCI2 is not only unable to induce Heymann's
nephritis or anti-BB antibody production by itself, but further-
more prevents, at least in the experimental conditions used, the
development of Heymann's nephritis in a strain normally highly
susceptible to the disease [71. Indeed, all LEW rats receiving
the control solution and immunized with BB developed typical
Heymann's nephritis. The course of the disease (proteinuria,
immune deposits, circulating antibodies) resembled closely that
described by Mendrick et al [21]. The minor differences re-
corded could be due to the antigen used or to the procedure of
immunization. In contrast, four of the ten rats injected with
HgCl2 and then immunized with BB did not develop glomerular
Ig deposits. In the remaining six the glomerular deposits as
assessed by immunofluorescence and electron microscopy were
small and scanty. Significant proteinuria was not detected in
any of these rats.
Several studies [12, 161 have recently demonstrated that
active Heymann's nephritis is the consequence of autoantibody
deposition on the gp330 antigen present on glomerular epithelial
cells. Our results show that HgCI2 interferes with antibody
production since rats immunized with BB antigen and injected
with HgCI2 had a lower anti-BB or arlti-gp330 antibody titer
than rats who were immunized with BB antigen only. It could
also be argued, however, that a tubular toxic substance such as
HgCl2 could modify the expression of gp330 by glomerular
and/or tubular epithelial cells. This was ruled out by in vitro
experiments which demonstrated that gp330 was expressed
identically in HgCI2-injected and in control rats. In addition, no
Fig. 4. Kidney cryostat section from a LEW rat injected with HgCI2 for
two weeks and sacrificed 72 hours after an intravenous injection of 200
,.d of rabbit anti-gp330 antiserum. Section was stained with a fluores-
ceinated sheep anti-rabbit IgG antiserum. Diffuse granular deposits are
observed along all the glomerular capillary walls. Note also the pres-
ence of a weak staining of the brush border of proximal convoluted
tubules (x 500).
difference was observed in the ability of passively administered,
heterologous anti-gp330 antibodies to bind to glomeruli.
The decreased antibody production induced by HgCl2 is not
restricted to gp330. Indeed, when challenged with SRBC,
HgCl2-injected LEW rats have a significantly lower antibody
response than control rats. These findings are in keeping with
our recent findings [22] showing that HgCl2 induces in that
strain an increase in the number of OX-8+ (suppressor/
cytotoxic) T cells together with a marked depression of T cell
functions (responsiveness to T cell mitogens and to al-
loantigens, ability to induce a local graft—versus—host reaction).
A role for antigen specific suppressor T cells has been previ-
ously demonstrated in Heymann's nephritis [23, 241. We now
demonstrate that the increase in the number of non-specific T
suppressor cells triggered by HgCl2 can also decrease autoanti-
body production and subsequent induction of Heymann's ne-
phritis. It is also possible that, in addition, the leakage of gp330
from damaged proximal convoluted epithelium could induce
antigen—specific suppressor cells. This hypothesis however
cannot account for the decreased antibody response to SRBC.
Another point to be discussed concerns the putative role of
tubular injury in the induction of either MN or granular tubular
deposits. Experiments from Mendrick et al strongly suggest
that the granular Ig deposits observed along the tubular base-
ment membrane during active [21] and passive [25] Heymann's
nephritis occur as a consequence of antigen leakage following
fixation of anti-BB antibodies on the BB of PCT. On the other
hand, it has also been suggested that tubular injury could
explain MN in patients with sickle cell anemia [10], in patients
treated with gold salts [26] or exposed to mercury [10, 271 and
in renal allograft recipients [28, 29]. Ueda et al [11] have
recently shown that guinea—pigs injected with gold salts develop
anti-BB antibodies and mesangial IgG deposits. Balbc/c mice
injected with HgCI7 develop anti-BB antibodies and subepithe-
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hal deposits [30]. However, it has not been proven that glomer-
ular deposits occur as a consequence of immunization towards
the BB antigen leaked out. The findings reported in this work do
not rule out the potential role of tubular damage in the induction
of MN since the immunodepressive effect of HgCI2 may blur a
hypothetical pathogenic process.
The apparent paradoxical effect of a given toxic agent de-
pending upon the strain tested is of more general interest. Drugs
such as D-penicillamine and rifampicin are well known agents
responsible in huiians, either for autoimmune disorders includ-
ing immunologically—mediated nephritis [31, 321 or for im-
munosuppression [33, 34]. There is, therefore, a close parallel
between clinical observations and results obtained in rats given
HgCl2. This agent is responsible for autoimmune nephritis in
several strains of rats [2], while it has an immunosuppressive
effect in LEW rats [22] and is able to down modulate the
nephritogenic response in Heymann's nephritis. This model
therefore represents a unique tool to evaluate the relationship
between genetics and drug—induced immune dysregulation. It is
tempting to speculate that, as in the graft—versus—host disease
[351, the involvement of different lymphocyte subsets depend-
ing upon genetics explain these opposite effects.
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